Rafarma Pharmaceuticals, Inc. (RAFA) Joins in Economic Development Coalition to Increase Biotech Growth in Terbuny, Russia.
11 Nov, 2013, 09:35 ET
MOSCOW, Nov. 11, 2013 /PRNewswire/ -- Executive leadership at Rafarma Pharmaceuticals (OTC:RAFA), recently met with the Governor of Lipetsk, Oleg Korolev, along with several government economic development representatives, including the Trade mission of the Russian Federation in Great Britain and announced plans for British investment in the region to create a "biopharmaceutical cluster" in Terbuny. The parties signed a project initiative to increase growth of the pharmaceutical industry in the region, finalize British investment and obtain manufacturing contracts for Rafarma and its biotech neighbors. As a certified and operating pharmaceutical manufacturer, Rafarma will be the lead company in this venture.
Governor Korolev described Rafarma as one of the best pharmaceutical enterprises of the Russian Federation, and praised the plant's full compliance with International Good Manufacturing Practices.
"Rafarma's state-of-the-art pharmaceutical plant in Terbuny has become the flashpoint for biopharma investment in Terbuny, Rafarma is leading the way," stated RAFA CEO Dave Anderson.
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit: http://www.rafarma.com
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.
SOURCE Rafarma Pharmaceuticals, Inc.
Share this article